04222nam a22006015i 4500 978-981-97-5077-1 DE-He213 20251030112930.0 cr nn 008mamaa 240901s2024 si | s |||| 0|eng d 9789819750771 978-981-97-5077-1 10.1007/978-981-97-5077-1 doi RS400-431 PSB bicssc SCI013040 bisacsh PNB thema PROTAC-Mediated Protein Degradation: A Paradigm Shift in Cancer Therapeutics [electronic resource] / edited by Mukesh Nandave, Priti Jain. 1st ed. 2024. Singapore : Springer Nature Singapore : Imprint: Springer, 2024. XXII, 385 p. 68 illus., 55 illus. in color. online resource. text txt rdacontent computer c rdamedia online resource cr rdacarrier text file PDF rda 1. Understanding the Ubiquitin Proteasome System - History and Revolution -- 2. PROTACs: Principles and Mechanisms -- 3. Structural Considerations and Chemistry of PROTAC -- 4. Advantages and Disadvantages of PROTACs -- 5. Novel Technologies in PROTAC Design -- 6. Future of trends in the design and development of PROTAC -- 7. Global Regulatory Requirements Applicable for PROTACs -- 8. Tissue-Specific Targeting Strategies with PROTAC Technology -- 9. Clinical Development OF PROTACs -- 10. Toxicological Aspects of PROTACs -- 11. PROTACs in the management of Prostate Cancer -- 12. Exploring the Role of PROTACs for the Treatment of Breast Cancer -- 13. Role of PROTACs in Hematological Malignancies -- 14. Artificial Intelligence and Machine Learning for Exploring PROTAC in Underutilized Cells -- 15. PROTACs in Treatment of Glioma -- 16. Proteolysis Targeting Chimera (PROTACs) an Attractive Technology in CVD Therapeutics: Opportunities and Challenges -- 17. Delivery systems - miniaturised PROTAC, Nano PROTAC, Aptamer-based RNA PROTAC. This book is a comprehensive coverage of the ubiquitin-proteasome system and its involvement in cancer progression, and the application of PROTACs in different types of cancer treatment. The book discusses a unique perspective and comprehensive knowledge of the potential of PROTACs to transform cancer therapies. It provides an overview of the history, mechanisms, chemistry, design considerations, and different technologies involved in PROTACs. Additionally, it explains the ubiquitin-proteasome system, its impact on various diseases, and the principles and mechanisms of UPS. The book also describes the chemistry and design aspects of PROTACs and their role in various types of cancers. Finally, it covers the pharmaceutics aspect of formulation design, global requirements, and toxicological aspects of PROTACs. This book is targeted at cancer researchers, medical oncologists, bioinformatics, computational biologists, pharmacologists, medicinal chemists, formulation scientists, regulatory authorities, and policy makers. Pharmaceutical chemistry. 67843 Pharmacology. 67844 Pharmacovigilance. 74275 Oncology. 70760 Drug delivery systems. Pharmacy. 64666 Pharmaceutics. 67846 Pharmacology. 67844 Drug Safety and Pharmacovigilance. 74276 Oncology. 70760 Drug Delivery. 69429 Pharmacy. 64666 Nandave, Mukesh. editor. edt http://id.loc.gov/vocabulary/relators/edt 74724 Jain, Priti. editor. edt http://id.loc.gov/vocabulary/relators/edt 83504 SpringerLink (Online service) Springer Nature eBook Printed edition: 9789819750764 Printed edition: 9789819750788 Printed edition: 9789819750795 https://doi.org/10.1007/978-981-97-5077-1 ZDB-2-SME ZDB-2-SXM 63005 63005